"Medical Journeys" chart a path each step of the way for physicians and patients and provide continual resources and support, ...

MCLEAN, VA / ACCESSWIRE / December 10, 2024 / Dr. Amir Bajoghli and his colleagues have recently published an insightful case ...

The US Food and Drug Administration (FDA) has approved nemolizumab for moderate-to-severe atopic dermatitis inadequately ...

Briquilimab is a monoclonal antibody commercialized by Jasper Therapeutics, with a leading Phase II program in Severe Combined Immune Deficiency (SCID).

About half of people with "chronic spontaneous urticaria," or CSU, the most common type of chronic hives, experience what ...

Dealing with urticaria, or hives can feel like an uncomfortable and frustrating experience, especially when the itching and redness seem relentless. Whether triggered by an allergic reaction ...

Opens in a new tab or window The study was broken into two groups of patients: patients who had a history of cold-induced urticaria, and this is diagnosed by either something called a TempTest ...

Jasper Therapeutics, Inc.'s Briquilimab shows promise in treating chronic urticaria and asthma, with potential market approval by 2027, offering significant revenue opportunities in large ...

Keywords: Chronic inducible urticaria; cold urticaria, cholinergic urticaria, contact urticaria, delayed pressure urticaria, immunoglobulin E, mast cells, patient-reported outcomes, provocation ...

1 Department of Dermatology, Southwest Hospital, Army Medical University, Chongqing, China 2 Department of Pathophysiology, Army Medical University, Chongqing, China Introduction: Chronic urticaria ...

Celltrion today announced that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is approved ...

Urticaria affects 10% to 25% of the population at some point in their life (Henderson, Fleischer, & Feldman, 2000). It is characterized by short-lived swellings of the skin, mouth, and genitalia ...